Market by Test Type, Treatment, and Country Outlook | Forecast 2023-2030
As per Triton Market Research’s report, the male infertility market in Asia-Pacific is projected to advance with a CAGR of 5.38% during the forecast period 2023-2030.
Report scope can be customized per your requirements - Request Free Sample Report
The
countries examined in the region include:
•
China
•
Japan
•
South Korea
•
India
•
ASEAN Countries
•
Australia & New Zealand
•
Rest of Asia-Pacific
The Asia-Pacific male infertility market’s growth is prompted by various
factors, including growing disposable income, surged awareness about male
infertility, technological advancements, and strategic initiatives. Besides this,
the region has witnessed the emergence of various fertility clinics, which
significantly boosts market growth. However, countries like South Korea, Japan,
and Singapore provide partial coverage for assisted reproductive technology,
which may restrict the market expansion over the forecast period.
In the region, China leads the male infertility
market with the highest share.
The nation’s rapid growth is due to the rising incidence of diseases, such as
diabetes, genetic abnormalities, and infections like chlamydia, gonorrhea,
mumps, and HIV. Furthermore, the increasing prevalence of male infertility has
led to the high adoption rates of assisted reproductive technology (ART),
significantly contributing to market growth. For instance, as of June 2021, China
had 539 ART-approved medical facilities and 27 sperm banks. These facilities
facilitate over one million IVF sessions annually.
Further, to boost birth rates, the Chinese government announced plans to
provide free fertility therapy to its residents through the national insurance
program. In this regard, the National Healthcare Security Administration
recently announced expanding coverage to assist couples with the expenses
associated with conception, including various ART methods, with in vitro
fertilization (IVF) being the most commonly performed procedure. This further
accelerates the male infertility market’s growth.
On the other hand, the Japanese male infertility market is anticipated
to witness significant growth due to a high prevalence of smoking and unhealthy
lifestyles, increased adoption of assisted reproductive technologies, and the
availability of reimbursements and insurance.
Assisted reproductive technology (ART) comprises various procedures to
treat infertility, including IntraCytoplasmic Sperm Injection (ICSI), in vitro
fertilization (IVF), frozen oocyte replacement, Intrauterine Insemination
(IUI), etc. In this regard, IVF has emerged as the most effective type of
assisted reproductive technology involving a series of procedures to assist
fertility, prevent genetic issues, and facilitate child conception. This
treatment has witnessed significant developments in recent years. For instance,
in 2022, the University of Adelaide collaborated with medical technology
company Fertilis to develop a micro-device tailored to males with low sperm
counts, enabling more IVF clinics to offer Intracytoplasmic Sperm Injection
(ICSI) as a treatment.
The market is segmented into treatment and test
type. The test type
further includes assisted reproductive technology and surgery and medications.
Some
of the prominent companies in the market include Aytu BioPharma, Zydus
Lifesciences Limited, CinnaGen Co, Sanofi SA, and Laboratory Corporation of
America Holdings.
Zydus Lifesciences Limited, formerly Cadila Healthcare Limited, is an
Indian multinational pharmaceutical company headquartered in Ahmedabad, India.
It specializes in producing generic medications. The company has research
facilities and manufacturing sites across India, as well as in Brazil and the United
States. With a global production network of 35 facilities adhering to strict
regulatory compliance standards, Zydus Lifesciences Limited offers customers
cost-effective pharmaceutical products in various dosage forms worldwide.
Key deliverables of the report:
● Market CAGR during the forecasting years 2023-2030
● Detailed data highlighting key insights, industry components, and market strategies
● Comprehensive information and estimation of the male infertility market revenue growth in the Asia-Pacific and its influence on the parent market
● In-depth study of forthcoming trends in consumer behavioral patterns
● A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces
●
A wide-ranging study of factors that will challenge the APAC male infertility
market’s growth during the upcoming years
Want to get specific insights? Our team of
analysts can customize this report based on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. ASIA-PACIFIC
MALE INFERTILITY MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. PARENT
MARKET ANALYSIS
2.2. IMPACT
ANALYSIS ON THE MALE INFERTILITY MARKET
2.2.1. COVID-19
IMPACT
2.2.2. UKRAINE-RUSSIA
WAR IMPACT
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
MATURITY ANALYSIS
2.5. KEY MARKET
STRATEGIES
2.5.1. COLLABORATIONS
2.5.2. PRODUCT
LAUNCHES
2.5.3. MERGERS
& ACQUISITIONS
2.5.4. BUSINESS
DIVESTITURES & EXPANSIONS
2.6. MARKET
DRIVERS
2.6.1. PREVALENCE
OF INFERTILITY
2.6.2. USE OF
ASSISTED REPRODUCTIVE TECHNOLOGIES
2.6.3. TECHNOLOGICAL
INNOVATIONS AND ADVANCEMENTS
2.7. MARKET
CHALLENGE
2.7.1. HIGH COST
OF TREATMENT
2.8. MARKET
OPPORTUNITIES
2.8.1. INCREASING
ACCEPTANCE OF MINIMALLY INVASIVE SURGERIES
2.8.2. GROWING
AVAILABILITY OF INFERTILITY TREATMENT DRUGS, PROCEDURES, AND DEVICES
2.8.3. GOVERNMENT
INITIATIVES TOWARD IMPROVING REIMBURSEMENT POLICIES
2.9. ANALYST
PERSPECTIVE
3. ASIA-PACIFIC
MALE INFERTILITY MARKET – BY TEST TYPE
3.1. DNA
FRAGMENTATION TECHNIQUE
3.2. OXIDATIVE
STRESS ANALYSIS
3.3. MICROSCOPIC
EXAMINATION
3.4. SPERM
AGGLUTINATION
3.5. COMPUTER-ASSISTED
SEMEN ANALYSIS
3.6. SPERM
PENETRATION ASSAY
3.7. OTHER
TEST TYPES
4. ASIA-PACIFIC
MALE INFERTILITY MARKET – BY TREATMENT
4.1. ASSISTED
REPRODUCTIVE TECHNOLOGY AND SURGERY
4.2. MEDICATIONS
5. ASIA-PACIFIC
MALE INFERTILITY MARKET – BY COUNTRY OUTLOOK
5.1. COUNTRY
ANALYSIS
5.1.1. CHINA
5.1.1.1. CHINA
MALE INFERTILITY MARKET FORECAST & PROSPECTS
5.1.2. JAPAN
5.1.2.1. JAPAN
MALE INFERTILITY MARKET FORECAST & PROSPECTS
5.1.3. INDIA
5.1.3.1. INDIA
MALE INFERTILITY MARKET FORECAST & PROSPECTS
5.1.4. SOUTH
KOREA
5.1.4.1. SOUTH
KOREA MALE INFERTILITY MARKET FORECAST & PROSPECTS
5.1.5. ASEAN
COUNTRIES
5.1.5.1. ASEAN
COUNTRIES MALE INFERTILITY MARKET FORECAST & PROSPECTS
5.1.6. AUSTRALIA
& NEW ZEALAND
5.1.6.1. AUSTRALIA
& NEW ZEALAND MALE INFERTILITY MARKET FORECAST & PROSPECTS
5.1.7. REST
OF ASIA-PACIFIC
5.1.7.1. REST
OF ASIA-PACIFIC MALE INFERTILITY MARKET FORECAST & PROSPECTS
6. COMPETITIVE
LANDSCAPE
6.1. HALOTECH
DNA
6.1.1. OVERVIEW
6.1.2. PRODUCT
PORTFOLIO
6.2. EMD
SERONO INC
6.2.1. OVERVIEW
6.2.2. PRODUCT
PORTFOLIO
6.2.3. KEY
STRENGTHS
6.2.4. KEY
CHALLENGES
6.3. ENDO
INTERNATIONAL PLC
6.3.1. OVERVIEW
6.3.2. PRODUCT
PORTFOLIO
6.3.3. KEY
STRENGTHS
6.3.4. KEY
CHALLENGES
6.4. VITROLIFE
6.4.1. OVERVIEW
6.4.2. PRODUCT
PORTFOLIO
6.4.3. KEY
STRENGTHS
6.4.4. KEY
CHALLENGES
6.5. BAYER AG
6.5.1. OVERVIEW
6.5.2. PRODUCT
PORTFOLIO
6.5.3. KEY
STRENGTHS
6.5.4. KEY
CHALLENGES
6.6. AYTU
BIOPHARMA
6.6.1. OVERVIEW
6.6.2. PRODUCT
PORTFOLIO
6.6.3. KEY
STRENGTHS
6.6.4. KEY
CHALLENGES
6.7. ZYDUS
LIFESCIENCES LIMITED
6.7.1. OVERVIEW
6.7.2. PRODUCT
PORTFOLIO
6.7.3. KEY
STRENGTHS
6.7.4. KEY
CHALLENGES
6.8. CINNAGEN
CO
6.8.1. OVERVIEW
6.8.2. PRODUCT
PORTFOLIO
6.8.3. KEY
STRENGTHS
6.8.4. KEY
CHALLENGES
6.9. SANOFI
SA
6.9.1. OVERVIEW
6.9.2. PRODUCT
PORTFOLIO
6.9.3. KEY
STRENGTHS
6.9.4. KEY
CHALLENGES
6.10. LABORATORY
CORPORATION OF AMERICA HOLDINGS
6.10.1. OVERVIEW
6.10.2. PRODUCT
PORTFOLIO
6.10.3. KEY
STRENGTHS
6.10.4. KEY
CHALLENGES
7. RESEARCH
METHODOLOGY & SCOPE
7.1. RESEARCH
SCOPE & DELIVERABLES
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE
1: ASIA-PACIFIC MALE INFERTILITY MARKET,
BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
TABLE
2: LIST OF COLLABORATIONS
TABLE
3: LIST OF PRODUCT LAUNCHES
TABLE
4: LIST OF MERGERS & ACQUISITIONS
TABLE
5: LIST OF BUSINESS DIVESTITURES &
EXPANSIONS
TABLE
6: ASIA-PACIFIC MALE INFERTILITY MARKET,
BY TEST TYPE, 2023-2030 (IN $ MILLION)
TABLE
7: ASIA-PACIFIC MALE INFERTILITY MARKET,
BY TREATMENT, 2023-2030 (IN $ MILLION)
TABLE
8: ASIA-PACIFIC MALE INFERTILITY MARKET,
BY COUNTRY OUTLOOK, 2023-2030 (IN $ MILLION)
FIGURE
1: MARKET MATURITY ANALYSIS
FIGURE
2: ASIA-PACIFIC MALE INFERTILITY MARKET,
BY TYPE, 2022 & 2030 (IN %)
FIGURE
3: ASIA-PACIFIC MALE INFERTILITY MARKET,
BY DNA FRAGMENTATION TECHNIQUE, 2023-2030 (IN $ MILLION)
FIGURE
4: ASIA-PACIFIC MALE INFERTILITY MARKET,
BY OXIDATIVE STRESS ANALYSIS, 2023-2030 (IN $ MILLION)
FIGURE
5: ASIA-PACIFIC MALE INFERTILITY MARKET,
BY MICROSCOPIC EXAMINATION, 2023-2030 (IN $ MILLION)
FIGURE
6: ASIA-PACIFIC MALE INFERTILITY MARKET,
BY SPERM AGGLUTINATION, 2023-2030 (IN $ MILLION)
FIGURE
7: ASIA-PACIFIC MALE INFERTILITY MARKET,
BY COMPUTER-ASSISTED SEMEN ANALYSIS, 2023-2030 (IN $ MILLION)
FIGURE
8: ASIA-PACIFIC MALE INFERTILITY MARKET,
BY SPERM PENETRATION ASSAY, 2023-2030 (IN $ MILLION)
FIGURE
9: ASIA-PACIFIC MALE INFERTILITY MARKET,
BY OTHER TEST TYPES, 2023-2030 (IN $ MILLION)
FIGURE
10: ASIA-PACIFIC MALE INFERTILITY
MARKET, BY TREATMENT, 2022 & 2030 (IN %)
FIGURE
11: ASIA-PACIFIC MALE INFERTILITY
MARKET, BY ASSISTED REPRODUCTIVE TECHNOLOGY AND SURGERY, 2023-2030 (IN $
MILLION)
FIGURE
12: ASIA-PACIFIC MALE INFERTILITY
MARKET, BY MEDICATIONS, 2023-2030 (IN $ MILLION)
FIGURE
13: ASIA-PACIFIC MALE INFERTILITY
MARKET, BY COUNTRY OUTLOOK, 2022 & 2030 (IN %)
FIGURE
14: CHINA MALE INFERTILITY MARKET
2023-2030 (IN $ MILLION)
FIGURE
15: JAPAN MALE INFERTILITY MARKET
2023-2030 (IN $ MILLION)
FIGURE
16: INDIA MALE INFERTILITY MARKET
2023-2030 (IN $ MILLION)
FIGURE
17: SOUTH KOREA MALE INFERTILITY MARKET
2023-2030 (IN $ MILLION)
FIGURE
18: ASEAN COUNTRIES MALE INFERTILITY
MARKET 2023-2030 (IN $ MILLION)
FIGURE
19: AUSTRALIA & NEW ZEALAND MALE
INFERTILITY MARKET 2023-2030 (IN $ MILLION)
FIGURE
20: REST OF ASIA-PACIFIC MALE
INFERTILITY MARKET 2023-2030 (IN $ MILLION)